HansBiomed Corporation Cash Flow Conversion Efficiency
HansBiomed Corporation cash flow conversion efficiency. Based on the latest financial reports, HansBiomed Corporation (042520) has a cash flow conversion efficiency ratio of 0.036x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩1.21 Billion ≈ $817.15K USD) by net assets (₩33.89 Billion ≈ $22.96 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of HansBiomed Corporation (2012–2025)
Cash flow conversion efficiency of HansBiomed Corporation from 2012 to 2025. This chart illustrates how HansBiomed Corporation's cash flow conversion efficiency has evolved over time, based on yearly financial data. View HansBiomed Corporation stock quote for real-time trading data and today's change.
HansBiomed Corporation Cash Flow Conversion Ratio Explained
HansBiomed Corporation cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
HansBiomed Corporation Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of HansBiomed Corporation ranked by their cash flow conversion efficiency. Also see 042520 company net worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Beijing Tongtech Co Ltd
SHE:300379
|
-0.012x |
|
Mnc Land Tbk
JK:KPIG
|
0.018x |
|
Ampco-Pittsburgh Corporation
NYSE:AP
|
0.035x |
|
United Utilities Group PLC
LSE:UU
|
0.310x |
|
Multitude SE
LSE:0R4W
|
0.102x |
|
NSE SA
PA:ALNSE
|
-0.027x |
|
LBS Bina Group Bhd
KLSE:5789
|
0.025x |
|
Bank Agris Tbk
JK:AGRS
|
0.027x |
Annual Cash Flow Conversion Efficiency for HansBiomed Corporation (2012–2025)
The table below shows the annual cash flow conversion efficiency of HansBiomed Corporation from 2012 to 2025. Review how much free cash does HansBiomed Corporation generate to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-09-30 | ₩33.89 Billion ≈ $22.96 Million |
₩318.34 Million ≈ $215.73K |
0.009x | -64.14% |
| 2024-09-30 | ₩67.12 Billion ≈ $45.49 Million |
₩1.76 Billion ≈ $1.19 Million |
0.026x | +135.06% |
| 2023-09-30 | ₩49.95 Billion ≈ $33.85 Million |
₩-3.73 Billion ≈ $-2.53 Million |
-0.075x | +20.13% |
| 2022-09-30 | ₩45.63 Billion ≈ $30.93 Million |
₩-4.27 Billion ≈ $-2.89 Million |
-0.094x | +71.60% |
| 2021-09-30 | ₩44.45 Billion ≈ $30.12 Million |
₩-14.64 Billion ≈ $-9.92 Million |
-0.329x | -445.66% |
| 2020-09-30 | ₩60.34 Billion ≈ $40.89 Million |
₩5.75 Billion ≈ $3.90 Million |
0.095x | +3.88% |
| 2019-09-30 | ₩84.07 Billion ≈ $56.97 Million |
₩7.71 Billion ≈ $5.23 Million |
0.092x | +15.14% |
| 2018-09-30 | ₩65.30 Billion ≈ $44.26 Million |
₩5.20 Billion ≈ $3.53 Million |
0.080x | -23.50% |
| 2017-09-30 | ₩53.73 Billion ≈ $36.41 Million |
₩5.60 Billion ≈ $3.79 Million |
0.104x | +1642.90% |
| 2016-09-30 | ₩46.82 Billion ≈ $31.73 Million |
₩-316.10 Million ≈ $-214.22K |
-0.007x | -108.41% |
| 2015-09-30 | ₩43.16 Billion ≈ $29.25 Million |
₩3.47 Billion ≈ $2.35 Million |
0.080x | +53.45% |
| 2014-09-30 | ₩39.39 Billion ≈ $26.69 Million |
₩2.06 Billion ≈ $1.40 Million |
0.052x | -34.24% |
| 2013-09-30 | ₩29.31 Billion ≈ $19.86 Million |
₩2.33 Billion ≈ $1.58 Million |
0.080x | +27.45% |
| 2012-09-30 | ₩24.04 Billion ≈ $16.29 Million |
₩1.50 Billion ≈ $1.02 Million |
0.062x | -- |
About HansBiomed Corporation
HansBiomed Corporation, together with its subsidiaries, engages in the research and development, production, and sale of medical materials for the procedure and the raw materials for medical supplies. The company provides ExFuse, a demineralized bone matrix with cancellous bone gel/putty; BellaFuse, a demineralized bone matrix; Genesis, a cancellous sponge block/filler; Pedi-Stick, a demineralize… Read more